High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer

New England Journal of Medicine

Volumn 349, Issue 1, 2003, Pages 7-16

  Rodenhuis, Sjoerd ^a   Bontenbal, Marijke ^b   Beex, Louk V A M ^c   Wagstaff, John ^d,e   Richel, Dick J ^f,g   Nooij, Marianne A ^h   Voest, Emile E ⁱ   Hupperets, Pierre ^e   Van Tinteren, Harm ^a   Peterse, Hans L ^a   TenVergert, Elisabeth M ^j   De Vries, Elisabeth G E ^j  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g Hospital Enschede   (Netherlands)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; THIOTEPA;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; SURVIVAL ANALYSIS; TAMOXIFEN; THIOTEPA;

EID: 0038036765     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa022794     Document Type: Article

References (25)

1. Rodenhuis S. The status of high-dose chemotherapy in breast cancer. Oncologist 2000;5:369-75.
2. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk breast cancer. J Clin Oncol 1993;11:1132-43.
3. Kodenhuis S, Richel DJ, van der Wall E, et al. A randomised trial ofhigh-dose chemotherapy and haematopoietic progenitorcell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 1998;352:515-21.
4. de Vries EGE, Meijs PJM, Rodenhuis S. Third-party payers and breast cancer study. J Clin Oncol 1998;16:809.
5. Rodenhuis S, Bontenbal M, Beex L, et al. Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carbopladn in operable breast cancer with 4 or more axillary lymph nodes. Prog Proc Am Soc Clin Oncol 2000;19:74a. abstract.
6. van der Wall E, Nooijen WJ, Baars JW, et al. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. Br J Cancer 1995;71:857-62.
7. Rodenhuis S, Baars J, Sehomagel JH, et al. Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa. Ann Oncol 1992;3:855-60.
8. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
9. Elston CW, Ellis IO. Pathological prog ostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
10. van Diest PJ, Baak JP, Matze-Cok P, et al. Reproducibility ofmitosis countingin 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 1992;23:603-7.
11. van de Vijver MJ, Peterse JL, Mooi WI, et al. Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-45.
12. Peters W, Rosner G, Vredenburgh J, et al. A prospective, randomized comparison of two doses ofcombination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 91141 NCIC MA-13. Prog Proc Am Soc Clin Oncol 1999;18:1a. abstract
13. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
14. Yamauchi H, Steams V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-56.
15. Lohrisch C, Piccart M. Her-2/neu as a predictive factorin breast cancer. Clin Breast Cancer 2001;2:129-35.
16. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6. [Erratum, N Engl J Med 1991;331:211.]
17. Nieto Y, Cagnoni PJ, Nawaz S, et al. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in highrisk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 2000;18:2070-80.
18. Nieto Y, Nawaz S, Jones RB, et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 2002;20:707-18.
19. Bewick M, Conlon M, Gerard S, et al. HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support. Bone Marrow Transplant 2001;27:847-53.
20. Schneeweiss A, Goemer R, Hensel MA, et al. Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy. Biol Blood Marrow Transplant 2001;7:332-42.
21. Kim YS, Konoplev SN, Montemurro F, et al. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res 2001;7:4008-12.
22. Bitran JD, Samuels B, Trujillo Y, Klein L, Schroeder L, Martirice J. Her-2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res 1996;9:1509-13.
23. Somlo G, Simpson JF, Frankel P, et al. Predictors oflong-term outcome following high-dose chemotherapyin high-risk primary breast cancer. Br J Cancer 2002;87:281-8.
24. Hensel M, Schneeweiss A, Sinn HP, et al. P53 is the strongest predictor ofsurvival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. Int Cancer 2002;100:290-6.
25. Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003;349:17-26.